Translational limitations of a rat-derived hybrid pharmacokinetic–toxicodynamic model for chemotherapy-induced hematologic toxicity in humans
Drug Metabolism and Pharmacokinetics · 2026-12 · 71 · 101554
DOI: 10.1016/j.dmpk.2026.101554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Pharmacokinetics, 2026-12. Verfasst von Shinji Kobuchi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan. Electronic address: kobuchi@mb.kyoto-phu.ac.jp. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Society for the Promotion of Science London.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Translational prediction of chemotherapy-induced hematologic toxicity remains challenging because toxicity profiles are shaped by species-specific hematopoietic regulation and inter-individual variability. This study evaluated the predictive performance of a previously developed rat-derived hybrid pharmacokinetic-toxicodynamic (PK-TD) model using real-world clinical data from patients receiving XELOX chemotherapy. Predicted leukocyte, neutrophil, and platelet profiles were compared with observed longitudinal blood cell counts using coverage probability and nadir-based metrics. The original model reproduced the overall temporal trends but underestimated clinical variability, with coverage probabilities of 0.43, 0.31, and 0.36 for leukocytes, neutrophils, and platelets, respectively. Empirical scaling of bias and variability improved coverage probabilities to 0.92, 0.84, and 0.90, respectively. Nadir coverage also improved, although neutrophil nadir depth bias persisted after scaling. Sensitivity analysis suggested that the transit compartment rate constant ktr influenced the temporal pattern of neutrophil suppression, although adjustment of ktr alone did not fully reproduce the clinical profile. These findings indicate that rat-derived hybrid PK-TD models can capture general hematologic trends but may underestimate clinical variability and cell type-specific nadir behavior. Careful consideration of clinical variability and hematopoietic maturation kinetics may improve preclinical-to-clinical translation of hematologic toxicity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan. Electronic address: kobuchi@mb.kyoto-phu.ac.jp.
- Department of Hospital Pharmacy, Graduate School of Medicine, The University of Osaka, Osaka, Japan; Department of Pharmacy, The University of Osaka Hospital, Osaka, Japan.
- Laboratory of Pharmacokinetics, Kyoto Pharmaceutical University, Kyoto, Japan.
Förderung
- Japan Society for the Promotion of Science
- Japan Society for the Promotion of Science London
Zitieren
APA
Kobuchi, S., Ikemura, K., Kobayashi, A., Okuda, M., & Ito, Y. (2026). Translational limitations of a rat-derived hybrid pharmacokinetic–toxicodynamic model for chemotherapy-induced hematologic toxicity in humans. Drug Metabolism and Pharmacokinetics, 71, 101554. https://doi.org/10.1016/j.dmpk.2026.101554
Vancouver
Kobuchi S, Ikemura K, Kobayashi A, Okuda M, Ito Y. Translational limitations of a rat-derived hybrid pharmacokinetic–toxicodynamic model for chemotherapy-induced hematologic toxicity in humans. Drug Metabolism and Pharmacokinetics. 2026;71:101554. doi:10.1016/j.dmpk.2026.101554
BibTeX
@article{Kobuchi2026,
author = {Kobuchi, Shinji and Ikemura, Kenji and Kobayashi, Akihide and Okuda, Masahiro and Ito, Yukako},
title = {Translational limitations of a rat-derived hybrid pharmacokinetic–toxicodynamic model for chemotherapy-induced hematologic toxicity in humans},
journal = {Drug Metabolism and Pharmacokinetics},
year = {2026},
volume = {71},
pages = {101554},
doi = {10.1016/j.dmpk.2026.101554}
}
EUVIMED